Boehringer Bails On Biosimilars Outside US
Executive Summary
In a strategic shift confirmed by the German company, BI's Humira biosimilar Cyltezo will only be launched in the US while its version of Avastin has been abandoned altogether.
You may also be interested in...
US Biosimilar Market – Who's In It For The Long Haul?
A biopharma conference in Mumbai hears how the US biosimilars landscape could potentially change over the long term when deep price cuts set in and payers have a greater say in matters. Might big pharma consider pulling out?
BI Bags Third Place For Humira Biosimilar in US With AbbVie Pact
Boehringer Ingelheim has settled litigation with AbbVie over Humira by striking a deal that allows it to launch its biosimilar adalimumab in the US from the start of July 2023.
Pfizer Decides Not To Challenge AbbVie's Humira Biosimilar Patents
Pfizer is the seventh company to enter licensing agreement with AbbVie; it has completed development program for its adalimumab candidate.